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atg4b: autophagy-related protein 4b 
ATP: Adenosine Triphosphate 
BMI: Body Mass Index 
eNOS: endothelial nitric oxide synthase 
IRI: Ischemia Reperfusion Injury 
JNK: c-Jun N-terminal kinase-1 
LC3: light chain 3 
NAFLD: Nonalcoholic Fatty Liver Disease 
NO: nitric oxide 
PKC: protein kinase C 
TNFα: tumor necrosis factor alpha 
UNOS: United Network for Organ Sharing 
WHO: World Health Organization
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Zusammenfassung 
 
Hintergrund: 
Der Bedarf an Lebertransplantaten ist in den letzten Jahrzehnten kontinuierlich gestiegen. Die 
Diskrepanz zwischen verfügbaren Spenderorganen und dem exponentiell ansteigendem 
Bedarf wird immer deutlicher. Eine Strategie das Problem anzugehen und den Spenderpool zu 
erweitern, ist die Verwendung marginaler Organe, wie z.B. steatotische Lebern oder Lebern 
älterer Spender. Es ist jedoch bekannt, dass marginale Lebern anfälliger für den 
Ischämie/Reperfusions-Schaden (IRI), eines der größten Risiken für post-operative 
Komplikationen und Morbidität, sind. Jüngste Studien legen nahe, dass einige dieser 
Mechanismen sowohl an der Entwicklung von Steatose und Seneszenz als auch dem IRI 
beteiligt sind. Wir stellten die Hypothese auf, dass therapeutische Ansätze, die auf diese 
Mechanismen abzielen, besonders nützlich sein könnten, um marginale Lebern vor IRI zu 
schützen. 
Ziel:  
Wir legten besonderes Augenmerk auf die Erforschung der gemeinsamen Mechanismen der 
Prozesse, die zu Steatose und Seneszenz sowie dem IRI beitragen. Uns interessierte die 
Identifikation und Evaluation einer therapeutischen Strategie, um steatotische Lebern vor IRI 
zu schützen. Weiterhin diskutierten wir die gemeinsamen Mechanismen und schlugen 
neuartige therapeutische Ansätze vor, die auf die gemeinsamen Mechanismen aller drei 
Prozesse - Steatose, Seneszenz und IRI - abzielen. 
Ergebnisse und Diskussion:  
Wir konnten zeigen, dass der intrazelluläre Energiestoffwechsel, die Entzündungsantwort und 
die Autophagie kritische Mechanismen sowohl in Steatose als auch in IRI sind. Wir stellten 
die Hypothese auf, dass therapeutische Strategien, die auf diese Mechanismen abzielen, 
besonders effektiv zum Schutz der steatotischen Lebern vor IRI eingesetzt werden könnten. 
Wir zeigten, dass die Behandlung mit Lithiumchlorid durch die Modulation der GSK3b and 
ERK1/2-Signalwege autophagieinduzierend wirkt und außergewöhnlich protektive Effekte 
beim IRI in steatotischen Lebern zeigte. Wir schlussfolgerten daher, dass Strategien, die auf 
gemeinsame Mechanismen, wie zB die Autophagie, abzielen, besonders nützlich sein könnten, 
um steatotische Lebern vor IRI zu schützen. 
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Wir legten in einen systematischen Review dar, dass der intrazelluläre Energiestoffwechsel, 
die Entzündungsantwort und die Autophagie sowohl in Seneszenz als auch in den IRI 
involviert sind. Wir haben festgestellt, dass therapeutische Strategien, die auf diese 
Mechanismen abzielen, ebenfalls besonders nützlich sind, um ältere Lebern vor IRI zu 
schützen. Erste Ergebnisse beim Einsatz von Lithiumchlorid legen dessen potentiellen Nutzen 
auch in diesem Zusammenhang nahe. Wir beobachteten, dass eine Behandlung mit 
Lithiumchlorid die Werte der Leberenzyme senkte und die nekrotischen Areale in älteren 
Lebern nach IRI reduzierte.  
Weiterhin diskutierten wir gemeinsame Mechanismen in den Steatose-, Seneszenz- und IRI-
Prozessen. Wir konnten zeigen, dass Steatose und Seneszenz auf unterschiedliche Weise den 
intrazellulären Energiestoffwechsel beeinträchtigen. Therapeutische Ansätze, die allein 
entweder den Glukose- oder den Fettstoffwechsel anvisieren, schützen ältere steatotische 
Lebern wahrscheinlich nicht vor IRI. Kombinierte Therapien oder die maschinelle ex-vivo 
Perfusionstechnik sollten als vielversprechende therapeutische Strategien in Erwägung 
gezogen werden. Die Entzündungsantwort ist der kritischste Prozess in sowohl Steatose als 
auch bei der Seneszenz. Therapeutische Ansätze, die die Entzündungsantwort adressieren, wie 
beispielsweise die Verwendung von Melatonin, haben nachweislich steatotische sowie auch 
seneszente Lebern vor IRI geschützt. Daher könnte Melatonin ein guter Kandidat sein, alte 
und steatotische Lebern vor IRI zu schützen. Autophagie ist ein weiterer Mechanismus, der 
sowohl in Steatose als auch Seneszenz eine Rolle spielt. In unserer Studie konnten wir zeigen, 
dass die Autophagieinduktion durch die Gabe von Lithiumchlorid steatotische Lebern vor IRI 
zu schützen vermochte. Da Autophagie in steatotischen und älteren Lebern beeinträchtigt ist, 
sollte die Induktion der Autophagie ebenfalls als eine der vielversprechenden Strategien 
angesehen werden, alte und steatotische Lebern vor IRI zu schützen. 
Schlussfolgerungen:  
Anhand einer Literaturauswertung konnten wir darlegen, dass intrazellulärer 
Energiestoffwechsel, Entzündungsantwort und Autophagie drei kritische Mechanismen 
darstellen, die den Steatose-, Seneszenz- und IRI-Prozessen gemein sind. Wir konnten zeigen, 
dass die Behandlung mit Lithiumchlorid die Regulation von Autophagie beeinflusst und 
erstaunliche protektive Effekte bei IRI in steatotischen Lebern zeigt. Weiterhin konnten wir 
zeigen, dass therapeutische Strategien, die auf die gemeinsamen Mechanismen in Steatose 
und Seneszenz abzielen, besonders nützlich sein könnten marginale Lebern, insbesondere alte 
und steatotische Lebern vor IRI zu schützen.
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Summary 
 
Background:  
The need for liver grafts has constantly increased in the past decades. The discrepancy 
between the declining availability of donor organs and the exponentially growing demand has 
becoming more and more obvious. To expand the donor organ pool by accepting marginal 
organs such as steatotic livers and aged livers is one of the strategies to solve this problem. 
However it is well accepted that marginal livers are more vulnerable to ischemia reperfusion 
injury (IRI), which is considered as one of the major risks of post-operative morbidity and 
mortality. Recent studies suggested that there were common mechanisms involved in both 
steatosis respectively senescence and the IRI processes. We hypothesized that therapeutic 
strategies targeting these common mechanisms might be especially useful in protecting 
marginal livers from IRI.  
Aim:  
We put our emphasis on exploring the common mechanisms in senescence/steatosis process 
and IRI process. We also aimed to identify and to evaluate one of these therapeutic strategies 
targeting the common mechanisms to protect steatotic livers from IRI. Furthermore, we 
discuss common mechanisms and suggest novel therapeutic strategies targeting common 
mechanisms in all three, steatosis, senescence and IRI processes. 
Results and Discussions:  
We demonstrated in a literature work up that intracellular energy metabolism, inflammatory 
response and autophagy are critical common mechanisms involved in both steatosis and IRI 
processes. We hypothesized that therapeutic strategies targeting these mechanisms might be 
particularly effective in protecting steatotic livers from IRI. We demonstrated that lithium 
chloride treatment induced autophagy and exhibited outstanding hepatoprotective effects 
during IRI in steatotic livers via a modulation of GSK3b and ERK1/2 pathways. We 
concluded that strategies targeting common mechanisms such as autophagy might be 
especially useful to protect steatotic livers from IRI. 
We concluded in a systematic review that intracellular energy metabolism, inflammatory 
response and autophagy are also involved in both senescence and IRI processes. We have 
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determined that the therapeutic strategies targeting these mechanisms are also particularly 
useful for protecting aged livers from IRI. Preliminary results using lithium chloride suggest 
its potential suitability also in this setting. We observed that treatment with lithium decreased 
the level of liver enzymes and reduced the area of confluent necrosis in aged livers after IRI. 
We further discussed common mechanisms in all three processes: steatosis, senescence and 
IRI. We demonstrated that steatosis and senescence processes are associated with different 
type of impairments of intracellular energy metabolism. Therapeutic strategies targeting only 
either glucose or lipid metabolism might be not expected to protect aged steatotic livers from 
IRI. Combination therapies or ex-vivo machine perfusion technique should be considered as 
promising therapeutic strategies. The inflammatory response is the most critical process in 
both steatosis and senescence processes. Therapeutic strategies targeting the inflammatory 
response, such as the use of melatonin, have been proven to protect both steatotic livers and 
aged livers from IRI. Therefore, melatonin could be a drug candidate to protect aged steatotic 
livers from IRI. Autophagy is another common mechanism in both steatosis and senescence 
processes. We demonstrated in our study that induction of autophagy by lithium chloride 
treatment protected steatotic livers from IRI. Since autophagy is inhibited in both steatotic and 
aged livers, induction of autophagy could also be considered as one of promising strategies to 
protect aged steatotic livers from IRI. 
Conclusions:  
We concluded that intracellular energy metabolism, inflammation and autophagy are three 
critical common mechanisms in steatosis, senescence and IRI processes. We concluded that 
lithium chloride treatment targets the regulation of autophagy and exhibits outstanding 
hepatoprotective effects during IRI in steatotic livers. Furthermore, we demonstrated that 
therapeutic strategies targeting common mechanisms in steatosis and senescence processes 
may be particularly helpful in protecting marginal livers such as aged steatotic livers from IRI.
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Introduction  
 
The need for liver grafts is rising constantly. Since the first case was performed by Thomas 
Starzl in 1963, human liver transplant is considered as the ultimate strategy for the patients 
with end-stage liver diseases, acute liver failure or hepatic malignancies (Zarrinpar und 
Busuttil 2013). Over the past decades, the number of liver transplant cases has constantly 
increased. According to the report from United Network for Organ Sharing (UNOS), 7841 
cases of liver transplantation were performed in the United States in 2016. However, the 
number of patients still on the waiting list has increased even faster. Based on UNOS data as 
of July 15, 2017, due to the lack of adequate donors over 20 patients die in average every day 
while waiting for transplantation in the United States. To ease the discrepancy between the 
substantially growing demand and the constant insufficient supply of donors, extending the 
donor pool is a matter of urgency. 
Organs from extended criteria donors, so called “marginal organs”, include steatotic livers 
and aged livers (Busuttil und Tanaka 2003). To expand the donor organ pool by widely 
accepting marginal organs is the most practical strategy to relieve the problem of donor 
organs shortage.  
However, the use of marginal livers is identified as an obvious risk of post-operative 
morbidity and mortality (Busuttil und Tanaka 2003). The increased risk is partly related to an 
increased IRI. It is well accepted that steatotic livers are more vulnerable to IRI (Chu et al. 
2013). It also has been demonstrated already in 1994, that old livers are more sensitive to 
hypoxia/reoxygenation stress (Le Couteur et al. 1994).  
The key mechanisms of hepatic IRI have been well explored since 1990s (Jaeschke et al. 1990, 
Jaeschke 1991, Jaeschke und Farhood 1991). It is well accepted that reperfusion injury occurs 
when blood supply returns to livers after a period of ischemia. There are two phases of 
reperfusion, which are defined as initial phase and later phase. During ischemia, the 
intracellular energy content of hepatocytes is depleted. Damaged mitochondria produce less 
adenosine triphosphate (ATP) but more free radicals, which leads to a direct hepatic damage 
(Fondevila et al. 2003). Inflammation plays the most critical role in both, initial and later 
phases in IRI (Jaeschke und Farhood 1991, Serracino-Inglott et al. 2001). The activation of 
Kupffer cells is considered as the central event of initial phase. The activation of neutrophils 
is the most critical event of later phase. The aggravated inflammatory response leads to both 
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programed and non-programed cell death, also known as apoptosis and necrosis. Recent 
studies reported that autophagy primarily affects the later phase of reperfusion (Cursio et al. 
2015). Autophagy protects hepatocytes during IRI by degrading dysfunctional mitochondria 
and increasing the intracellular energy content. 
Recent studies suggested that there are common mechanisms in both steatosis/senescence and 
IRI processes. Intracellular energy metabolism, inflammatory response and autophagy are 
considered to be involved in these processes. These findings support the hypothesis that 
therapeutic strategies targeting these central mechanisms might be especially useful in 
protecting marginal livers from IRI.  
In this study, we want to investigate common mechanisms in steatosis, senescence and IRI 
processes, to identify potential therapeutic strategies targeting these mechanisms and to 
evaluate one of these therapeutic strategies to protect steatotic and aged livers from IRI in a 
rat model.
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Hypotheses 
 
Based on the described considerations we raise the following hypothesis: 
• Steatosis, senescence and IRI share common mechanisms. 
• Therapeutic strategies targeting the common mechanism of steatosis, senescence and 
IRI processes might be especially useful in protecting marginal livers from IRI.
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Aims 
 
We set three aims for this study: 
• To identify common mechanisms and to identify potential therapeutic strategies 
targeting common mechanisms in steatosis and IRI processes as well as to evaluate 
one of these therapeutic strategies to protect steatotic livers from IRI.  
• To identify common mechanisms and to identify potential therapeutic strategies 
targeting common mechanisms in senescence and IRI processes. 
• To discuss common mechanisms and to suggest novel therapeutic strategies targeting 
common mechanisms in all three, steatosis, senescence and IRI processes. 
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Study Design 
 
In order to reach the aims we designed a study composed of three corresponding steps: 
• Generate a literature work up to identify the common pathophysiological mechanisms 
in steatosis and IRI processes and to identify promising therapeutic strategies to 
protect steatotic livers from IRI. Select and evaluate one of the strategies to protect 
steatotic livers from IRI in a rat model. 
• Generate a systematic review to identify the pathophysiological mechanisms rendering 
aged livers highly susceptible to IRI and identify promising therapeutic strategies to 
protect aged livers from IRI. 
• Discuss common mechanisms in steatosis, senescence and IRI processes to generate 
novel hypothesis for further testing of promising therapeutic strategies. 
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Results and Discussion Part 1: 
IRI in steatotic livers and the protective effect of the autophagy inducing drug lithium 
chloride 
 
1a. Pathophysiology of IRI in hepatic steatosis and potential therapeutic strategies.  
In 21th century, the obesity rate of the human population is constantly rising. A fact sheet 
from World Health Organization (WHO) in 2014 noted that more that 13% of adults, equal to 
600 million people, were obese (Body mass index (BMI) ≥30). Nearly 2 billion adults were 
overweight with a BMI ≥ 25. High obesity rate is associated with a high incidence rate of 
nonalcoholic fatty liver disease (NAFLD) (Rinella 2015). Due to the fact that NAFLD is 
normally a silent disease, the knowledge of the exact incidence of the world is still limited. 
According to studies of different countries, NAFLD affects 10% to 24% of general population 
or 57.5% to 74% of obese population (Obika und Noguchi 2012).  
Accepting steatotic livers is a promising strategy to expand the donor organ pool. However 
previous studies reported that using steatotic liver leads to an increased risk for postoperative 
morbidity and mortality after liver transplantation due to an increased IRI (Reiniers et al. 
2014). 
From the early description of NAFLD, the pathogenesis of this disease is still not fully 
understood. Nevertheless, intracellular energy metabolism, inflammation and autophagy are 
considered as three key mechanisms involved in the development of NAFLD (Rinella 2015, 
Byrne und Targher 2015, Lavallard und Gual 2014).  
It is well known that the intracellular energy metabolism disorder, especially the lipid disorder, 
plays a central role in the development of NAFLD. As a result of the energy metabolism 
disorder, fat accumulates in hepatocytes. The aggravated accumulation of fat in hepatocytes 
ultimately leads to a NAFLD (Rinella 2015).  
The activation of the inflammatory response is considered to play a critical role in the 
development of NAFLD. Mixed inflammatory cell infiltration is one of the most typical 
biopsy features in livers with steatohepatitis. The activation of inflammatory response is also 
considered as the major reason leading to hepatic fibrosis and ultimately even to hepatic 
cirrhosis, the alter stages of NAFLD (Rinella 2015).  
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Recent studies have also shown that autophagy plays a key role in the development of 
steatosis. It is reported that hepatic steatosis is associated with a reduced autophagic flux 
(Lavallard et al. 2012). Autophagy involves the recycling of dysfunctional organelles, and is 
essential to the maintenance of hepatic metabolism. As a self-protective response, autophagy 
protects hepatocytes from different types of stress (Yorimitsu und Klionsky 2005, Codogno 
und Meijer 2005). The impairment of autophagy weakens the ability of hepatocytes to resist 
steatohepatitis. Liu et al. demonstrated in a comprehensive review that steatosis impaired 
autophagy via a modulation of insulin-mTOR signaling pathway in mice (Liu et al. 2009). 
Furthermore, a number of studies suggested that activation of autophagy ameliorates hepatic 
steatosis (Sinha et al. 2014, Lin et al. 2013, Singh et al. 2009). The accumulation of fatty acids 
is one of the main pathological features in the development of NAFLD. Since autophagy 
maintains intracellular energy levels via a recycling of cellular components including the lipid 
droplets, induction of autophagy to reduce hepatic triglyceride levels is a promising strategy 
to ameliorate hepatic steatosis. 
As described before, IRI process is dominated by three critical mechanisms: intracellular 
energy metabolism, inflammatory response and autophagy. Intracellular energy metabolism 
plays a critical role in ischemia phase and early phase of reperfusion. Inflammatory response 
is the most pivotal mechanism in both early and later phases of reperfusion. Autophagy 
mainly affects the later phase of reperfusion. 
Since intracellular energy metabolism, inflammatory response and autophagy are involved in 
both steatosis and IRI processes, therapeutic strategies targeting these mechanisms might be 
particularly effective in protecting steatotic livers from IRI. Studies investigating therapeutic 
strategies to protect steatotic liver grafts against IRI in are listed in following Table 1. 
Therapeutic strategies targeting intracellular energy metabolism are very efficient to protect 
steatotic livers from IRI. As early as 2009, Evans et al. demonstrated that vitamin E succinate 
treatment protects fatty livers from warm IRI by enhancing the hepatic energy status. Zaoualí 
et al. demonstrated that melatonin protected fatty livers from cold IRI by relieving 
intracellular energy disorder. It is well accepted that ex-vivo machine perfusion technique 
significantly increases the level of intracellular energy contents and reduces oxygen free 
radicals release. Bruinsma et al. reported that subnormothermic machine perfusion is 
particularly useful for protecting steatotic livers from IRI. 
Results and Discussion Part 1 - 16 - 
Therapeutic strategies targeting the inflammatory response are also well explored in steatotic 
livers. A series of drugs have been reported to prevent hepatic IRI by addressing the 
inflammatory response. Zaoualí et al. demonstrated that melatonin protected steatotic livers 
from IRI by modulation the nitric oxide (NO) pathway. Other inflammatory regulating drugs 
such as ankaflavin (inhibition of the activity of Kupffer cells) and theaflavin (regulation of 
TNFα pathway) are also reported as promising therapeutic strategies to protect steatotic liver 
grafts against IRI. 
Current experimental evidence regarding the efficacy of targeting autophagy to protect 
steatotic livers from IRI is still limited. However, in 2011 a clinical study suggested that 
ischemic preconditioning protects fatty livers from IRI by inducing autophagy (Degli Esposti 
et al. 2011).  
Therefore, we hypothesize that a therapeutic strategy inducing autophagy is especially 
effective to reduce IRI in steatotic livers. A number of drugs such as rapamycin (Pan et al. 
2009), carbamazepine (Hidvegi et al. 2010), verapamil (Kania et al. 2017) as well as lithium 
chloride (Motoi et al. 2014) were proven to induce autophagy. Liu et al. demonstrated that 
lithium chloride treatment protects normal livers from IRI via a modulation of autophagy (Liu 
et al. 2013). Since autophagy is involved into both steatosis and IRI processes, induction of 
autophagy by lithium chloride treatment is also a promising to protect steatotic livers from IRI. 
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Table 1: Therapeutic strategies against hepatic IRI in steatotic livers 
Authors and Year Animal model Steatosis model IRI model Key statement 
(Evans et al. 2009) # C57BL/6 mice Leptin -/- 
knockout 
Total liver warm 
IRI 15 min 
Vitamin E succinate protects fatty livers from IRI by enhancing 
hepatic energy status and preventing oxidative damage.  
(Andraus et al. 2010) Wistar rats protein-free diet 
for 3 weeks 
70% liver warm 
IRI 
60 min 
S-Nitroso-N-Acetylcysteine protects against IRI in fatty livers 
but not in normal livers. 
(Zaouali et al. 2011) #,$ Homozygous Zucker rats Cold IRI for 24 
hours 
Melatonin protects normal and fatty livers from IRI by 
addressing intracellular energy disorder and inflammatory 
response. 
(Luo et al. 2012) $ C57BL/6 mice Methionine- and 
choline-deficient 
high fat diet for 2 
weeks 
Total liver warm 
IRI 15 min 
Theaflavin protects fatty livers from IRI by addressing oxidant 
stress, inflammatory response and apoptosis.  
(Yang et al. 2014) Sprague-
Dawley rats 
Methionine- and 
choline-deficient 
diet for 12 weeks/ 
High fat diet for 8 
weeks 
70% liver warm 
IRI 
60 min 
Losartan protects fatty livers from IRI. 
(Bejaoui et al. 2015a) Homozygous Zucker rats Cold IRI for 24 
hours 
Acetazolamide protects fatty livers from IRI. 
(Bejaoui et al. 2015b) Homozygous Zucker rats Cold IRI for 24 
hours 
Carbonic anhydrases II protects fatty livers from IRI. 
(Matsuda et al. 2015) $ C57BL/6 mice High fat diet for 9 
weeks 
70% liver warm 
IRI 
60 min 
Activated protein C protects normal and fatty livers from IRI by 
addressing inflammatory response.  
(Cahova et al. 2015) $ Wistar rats High fat diet for 
10 weeks 
Total liver warm 
IRI 20 min 
Metformin protects fatty livers from IRI by addressing reactive 
oxygen species formation and inflammatory response.  
(Yang et al. 2015) $ C57BL/6 mice High fat diet for 4-
8 weeks 
70% liver warm 
IRI 
60 min 
Ankaflavin protects fatty livers from IRI by modulating the 
function of Kupffer cells.  
# Therapeutic strategies targeting energy metabolism 
$ Therapeutic strategies targeting inflammatory response 
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1b. Induction of autophagy reduces ischemia/reperfusion injury in steatotic rat livers  
Introduction: 
To investigate whether inducing autophagy by treatment with lithium chloride could protect 
fatty livers from IRI, a rat model of hepatic steatosis was used in this study. After induction of 
moderate hepatic steatosis, rats were pretreated with lithium chloride and then subjected to 70% 
selective warm ischemia for 60 minutes. In this experiment, autophagy, inflammation, 
apoptosis and potential related signal transduction pathways were investigated.  
Summary: 
In the first part of this study, we demonstrated that therapeutic strategies targeting 
intracellular energy metabolism, inflammatory response and autophagy are promising to 
protect steatotic livers from IRI. Since autophagy is a common mechanism of both steatosis 
and IRI processes, it was of great interest to extend this setting to steatotic livers. Therefore, 
we validated the hepatoprotective effect of autophagy in a rodent model of warm ischemia of 
the steatotic liver.  
We confirmed in this study, that steatotic livers are more sensitive to IRI than normal livers. 
Comparing our results with the results of Liu et al., at 6 h after reperfusion, the plasma ALT 
level in steatotic livers was 20% higher than the level in normal livers.  
After lithium chloride treatment, liver enzymes were reduced by half at 6 h after reperfusion. 
The inflammatory response, apoptosis and necrosis were also reduced in the lithium chloride 
treatment groups. The expression levels of phospho-GSK3b and phospho-ERK1/2 were 
higher in the treatment group compared to the control group. We demonstrated that treatment 
with lithium modulated both GSK3b and ERK1/2 pathways, induced autophagy and protected 
steatotic livers from IRI. 
Conclusion: 
In conclusion, lithium chloride treatment exhibited outstanding hepatoprotective effects 
during IRI in steatotic livers via a regulation of autophagy. Furthermore, we demonstrated that 
simultaneous modulation of GSK3b and ERK1/2 pathways is an interesting strategy to reduce 
IRI. This strategy might be especially useful in steatotic livers with an underlying impairment 
of autophagy. 
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A manuscript entitled “Induction of autophagy reduces ischemia/reperfusion injury in 
steatotic rat livers” was published by Journal of Surgical Research (IF 2.198) and can be 
accessed via https://dx.doi.org/10.1016/j.jss.2017.04.012.
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Induction of autophagy reduces ischemia/reperfusion injury in steatotic rat livers 
 
Chunyi Kan, Anding Liu, Haoshu Fang, Olaf Dirsch, Uta Dahmen and Michael Boettcher  
Journal of Surgical Research; August 2017 (216) 207-218.  
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Results and Discussion Part 2: 
IRI in aged livers – the energy metabolism, inflammatory response and autophagy  
 
Introduction: 
Over the past century, the life expectancy of mankind has been greatly improved. According 
to the WHO, the life expectancy at birth in the United States did increase from 76.8 in 2000 to 
79.3 in 2015. The United Nations’ World Population Ageing Report 2015 noted that the 
global population aged 60 or over has increased from 607.1 million in 2000 to 900.9 million 
in 2015 and is projected to rise further to 1402.4 million in 2030 and 2092.0 million in 2050. 
The population aged 80 or over are expected to increase by 6-fold, from 71.0 million in 2000 
to 434.4 million in 2050.  
Since 2000s, the physiological changes of liver in senescence process were explored by a 
series of studies (Hoare et al. 2010, Kim et al. 2015). The impaired intracellular energy 
metabolism, the enhanced inflammatory response and the reduced autophagic flux were 
considered as the most important physiological processes in aging. Impaired mitochondria in 
aged livers produce less ATP but generate more free radicals. The accumulation of free 
radicals was considered one of the major forces of senescence process (Harman 1956). It is 
also reported that compared to normal livers, aged livers are more vulnerable to external stress. 
The increased vulnerability of aged livers is associated with an increased inflammatory 
response (Matsutani et al. 2007) and a decreased autophagy (Rubinsztein et al. 2011). 
To better understand how senescence affects liver IRI, a literature work up spanning over the 
existing studies was generated.  
Summary: 
In the second part of this study, we systematically reviewed the pathophysiological 
mechanisms of IRI in aged livers. We identified therapeutic strategies targeting intracellular 
energy metabolism, inflammation or autophagy which might be also especially useful to 
protect aged livers from IRI.  
Similar to steatotic livers, aged livers are also more sensitive to IRI. Current experimental 
evidence for therapeutic strategies targeting intracellular energy metabolism, inflammation or 
autophagy protecting aged livers from IRI are promising, but still limited. Selzner et al. 
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demonstrated that treatment with d-glucose, which increases the hepatocellular intracellular 
energy content, reversed the reduced effect of ischemic preconditioning in aged livers. 
Selzner et al. and Kireev et al. presented in their studies that treatment with pentoxifylline and 
melatonin, which are considered as inflammatory inhibitors, significantly reduced IRI related 
hepatic damage in aged livers.  
We generated own preliminary but promising experimental evidence that using lithium 
chloride as a drug targeting inflammatory response and autophagy alleviates the IRI in aged 
livers. Therefore, it is also of great interest to explore other therapeutic strategies targeting 
autophagy in future. 
Conclusion: 
In conclusion, the intracellular energy metabolism, inflammatory response and autophagy are 
three critical common mechanisms in both senescence process and IRI process. It is expected 
that therapeutic strategies targeting these three processes are particularly useful for aged livers 
with an increased risk of IRI after primary liver surgery. 
A comprehensive review entitled “Ischemia-Reperfusion Injury in Aged Livers - The Energy 
Metabolism, Inflammatory Response, and Autophagy” was published by Transplantation (IF 
3.678) and can be accessed via https://doi.org/10.1097/TP.0000000000001999.
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Results and Discussion Part 3: 
Discussion: Common mechanisms in steatosis, senescence and IRI processes and 
resulting hypothesis for the design of promising therapeutic strategies 
 
We demonstrated in part 1 that intracellular energy metabolism, inflammation and autophagy 
are common mechanisms shared by steatosis and IRI processes. Therapeutic strategies 
targeting these mechanisms such as induction of autophagy by lithium chloride treatment can 
reduce IRI in steatotic livers. We have demonstrated in part 2 that these mechanisms are also 
shared by senescence and IRI processes. Therapeutic strategies targeting these mechanisms 
are also especially useful to protect senescent livers from IRI. 
However, marginal livers of the future are not only steatotic livers or aged livers but also 
livers suffering from both, age and steatosis, at the same time. The overwhelming changes in 
life style leading to the growing prevalence of obesity and the demographic changes leading 
to the increased number of senescent donors will result in a higher number of donor organs 
affected by both, steatosis and age. In our study, we identified and evaluated therapeutic 
strategies targeting intracellular energy metabolism, inflammation and autophagy that are 
promising to protect steatotic or aged livers from IRI. Since steatosis process and senescence 
process sharing common mechanisms, therapeutic strategies targeting these mechanisms may 
also be promising to protect aged and steatotic livers from IRI. On the basis of these two 
papers and previous studies of common mechanisms in steatosis, senescence and IRI 
processes, we want to further generate a novel hypothesis for reducing IRI in the aged 
steatotic liver. 
Intracellular energy metabolism 
Intracellular energy metabolism disorder is an important factor of both steatosis and 
senescence processes. It has been shown that therapeutic strategies targeting intracellular 
energy metabolism can protect either steatotic livers or aged livers from IRI. Nevertheless, the 
mechanisms of intracellular energy metabolism disorder in steatosis and senescence processes 
are different.  
The fat accumulation resulting from lipid disorder plays a critical role in the development of 
NAFLD. Samuel et al. demonstrated in a series of studies that feeding rats a high fat diet 
resulted in an activation of the protein kinase C (PKC) and c-Jun N-terminal kinase-1 (JNK). 
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The activation of PKC and JNK leads to a reduced tyrosine phosphorylation level of insulin 
receptor substrate by regulating the activity of insulin receptor kinase and leads to a hepatic 
insulin resistance. According to the studies of Samuel, hepatic insulin resistance results in an 
impairment of insulin-mediated suppression of lipolysis and does ultimately cause the fat 
accumulation in hepatocytes (Samuel et al. 2010, Samuel et al. 2007, Samuel et al. 2004).  
However, in aged livers, the intracellular energy metabolism disorder is mainly associated 
with dysfunctional mitochondria and reduced intracellular energy content. The impairment of 
the mitochondria function is one of the major forces of the senescence process. On one hand, 
mitochondria in aged livers are producing less ATP resulting in a reduced intracellular energy 
level. On the other hand, more free radicals generated by mitochondria in aged livers lead to a 
higher level of oxidative stress (Harman 1956, Cadenas und Davies 2000, Navarro und 
Boveris 2007).  
As we described before, the development of steatosis is mainly related to a disturbance in the 
lipid metabolism leading to a lipid accumulation in the hepatocytes whereas and the aging is a 
result of impairment in the function of mitochondria. Therefore intracellular energy 
metabolism is not affected in the same way and therefore cannot be considered as a common 
mechanism in both processes. Therapeutic strategies targeting only the glucose or lipid 
metabolism might be not suitable to protect aged steatotic livers from IRI. Combination 
therapies such as Vitamin E succinate and glucose targeting both lipid and glucose 
metabolisms could be more promising therapeutic strategies in aged steatotic livers. 
In addition, recently published studies suggested that ex-vivo machine perfusion is a 
promising therapeutic strategy that can significantly increase intracellular energy levels and 
reduce the generation of oxygen free radicals during graft transportation (Marecki et al. 2017). 
Depending on the temperature of the perfusate, the machine perfusion may be hypothermic, 
subnormothermic or normothermic (Marecki et al. 2017). Bessems et al. demonstrated that 
preservation of steatotic livers by hypothermic machine perfusion reduces hepatic damage 
during cold ischemia (Bessems et al. 2007). Due to the lipid accumulation, the hepatocyte size 
increases substantially in steatotic livers, resulting in a reduced sinusoidal space and 
ultimately leading to a reduced hepatic flow (Rinella 2015). The observation that machine 
perfusion is particularly effective in steatotic livers may be associated with the mechanical 
pressure improving the hepatic flow (Bessems et al. 2007). However, up to now, no 
systematic study dedicated to explore the effect of machine perfusion on the age-related 
augmentation of hepatic IRI was yet performed. A case was reported recently of using 
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normothermic machine perfusion successful preserving the viability of a graft from an 83 year 
old brain dead donor (Pezzati et al. 2017). Since ex-vivo machine perfusion protects steatotic 
liver donors and other type of marginal liver donors from IRI, it is of great interest to also 
explore the effect of machine perfusion on aged livers or even aged steatotic livers in the 
future. 
Inflammatory response 
The inflammatory response is considered to be the most pivotal mechanism in both steatosis 
development and in aging. On one hand, it is well accepted that the inflammatory response 
plays a critical role in the development of NAFLD. To a certain extent, NAFLD itself is 
considered as a chronic inflammatory disease. The inflammatory response is considered as the 
major reason leading to hepatic fibrosis and cirrhosis (Rinella 2015). On the other hand, aged 
livers are also more vulnerable to IRI-induced inflammatory response. As described in detail 
before, heat shock protein 70 (HSP70) plays a critical role in the inflammatory response 
following hepatic ischemic damage. Okaya et al. demonstrated that aged livers produced less 
HSP70 than young livers. The activation of HSP70 protected the aged livers from the 
aggravated inflammatory response after IRI by reducing liver nuclear factor-κB activation and 
by reducing serum macrophage inflammatory proteins and tumor necrosis factor alpha (TNFα) 
generation (Okaya et al. 2005). Besides, the expressions of other inflammatory cytokines such 
as IL6 were also significantly increased in aged mice compared to younger ones (Matsutani et 
al. 2007).  
Therapeutic strategies targeting the inflammatory response have been well studied in marginal 
livers. Melatonin (N-acetyl-5-methoxytryptophan) is mainly produced by pineal gland in 
humans. The major biological function of melatonin is to regulate the circadian rhythm. 
Moreover, it was reported recently that melatonin also presented a strong activity to protect 
against oxidative stress (Claustrat und Leston 2015). In 2011 and 2012, two independent 
studies employing different rodent models demonstrated that melatonin therapy protected 
both steatotic livers and aged livers from IRI by regulating the inflammatory response 
(Zaouali et al. 2011, Kireev et al. 2012).  
Previous studies demonstrated that melatonin treatment exhibited hepatoprotective effects 
during IRI in marginal livers via a regulation of NO signaling pathway. Zaoualí et al. reported 
in 2011 that melatonin protected against hepatic IRI by inducing the generation of NO in 
homozygous Zucker rats (Zaouali et al. 2011). NO produced by endothelial NO synthase 
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(eNOS) maintained the hepatic microcirculation, inhibited leukocyte adhesion and migration 
as well as inhibited platelet aggregation (Fleming 2010). The activation of NO protected 
against hepatic IRI by relieving the oxidative stress and reducing the inflammatory response 
(Thomas et al. 2008). Melatonin induced NO formation and activation via an overexpression 
of heme oxygenase-1 (Li et al. 2014). Compared with normal livers, the activity of NO signal 
pathway was inhibited in both steatotic and aged livers during IRI. Persico et al. demonstrated 
recently in a clinical study that a marked eNOS dysfunction has been observed in the liver 
from NAFLD patients. This study suggested that the eNOS dysfunction is a peculiar and 
essential mechanism in the occurrence of NAFLD (Persico et al. 2017). Knott et al. 
demonstrated in a comprehensive review that NO signaling is also impaired with aging. The 
impaired NO signaling was considered to be involved in the development of a variety of 
geriatric diseases such as atheromatous disease, aortic valve stenosis and systolic 
hypertension (Knott und Bossy-Wetzel 2010).  
Overall, the NO signaling pathway was inhibited in both steatotic livers and aged livers. Due 
to the fact that treatment with melatonin reduced hepatic IRI by inducing the activation of NO 
signaling pathway, we can raise the hypothesis that melatonin treatment can prevent IRI also 
in aged steatotic livers. Therefore, it is of great interest to further explore the protective effect 
of melatonin in aged steatotic livers. 
Besides melatonin, a number of other drugs also protect marginal livers from IRI. Luo et al. 
demonstrated that theaflavin treatment attenuates IRI in steatotic livers via a regulation of 
TNFα pathway (Luo et al. 2012). Yang et al. reported that ankaflavin protects steatotic livers 
from IRI by inhibiting the function of Kupffer cells (Yang et al. 2015). In addition, metformin 
(Cahova et al. 2015) and pentoxifylline (Selzner et al. 2009) are proven to reduce IRI in 
marginal livers by targeting inflammatory response. Since both steatosis process and 
senescence process aggravates inflammatory response, it is of great interest to explore the 
protective effect of these drugs in other type of marginal livers and even in aged and steatotic 
livers. 
Autophagy 
An impairment of autophagy was also observed in both, steatotic livers and aged livers. In 
2009, Liu et al. reported that steatosis development affects insulin-mTOR signaling pathway 
and inhibits autophagy (Liu et al. 2009). In 2011, Wang et al. demonstrated that the 
expression level of autophagy-related protein 4b (atg4b) is reduced in aged liver. The reduced 
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expression of atg4b regulates light chain 3 (LC3) activity and inhibits autophagy (Wang et al. 
2011).  
Since autophagy is reduced in both steatotic and aged livers, it is also of great interest to 
explore the protective effect of induction of autophagy in aged and steatotic livers undergoing 
hepatic IRI. Current experimental evidence for therapeutic strategies targeting autophagy in 
hepatic IRI in aged livers is still limited. In this study, we generated own preliminary data that 
using lithium chloride as a drug targeting autophagy protected against IRI in aged livers. This 
result was indicated by lower serum liver enzyme levels and less necrotic areas (Figure 1).  
Since induction of autophagy by lithium chloride treatment reduced IRI in both normal and 
steatotic livers and we already generated preliminary evidence regarding the effect in aged 
livers, it is also of great interest to further explore the protective effect of autophagy in the 
setting of aged steatotic livers in IRI.  
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Figure 1: Treatment with lithium chloride reduces (A) serum liver enzyme levels and 
reduces (B) necrotic areas after IRI in aged livers
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Conclusion 
 
Taken together, we concluded that intracellular energy metabolism, inflammation and 
autophagy are three critical mechanisms which are involved in steatosis, senescence and IRI 
processes.  
Previous studies and our experiments demonstrated that therapeutic strategies targeting one or 
more of these three mechanisms are especially useful to protect steatotic and aged livers or 
even “aged steatotic livers” from IRI.  
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